Current sequencing strategies in HER2+ breast cancer include trastuzumab, pertuzumab, and a taxane in the first line, followed by T-DXd in the second line and T-DM1 or tucatinib-containing regimens in later lines. This evidence concerns the gene ERBB2 and breast carcinoma.